List of Excipients in Branded Drug AUGMENTIN ES-600

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Dr Reddys Laboratories Inc	AUGMENTIN ES-600	amoxicillin and clavulanate potassium	43598-003	ASPARTAME
Dr Reddys Laboratories Inc	AUGMENTIN ES-600	amoxicillin and clavulanate potassium	43598-003	CARBOXYMETHYLCELLULOSE SODIUM
Dr Reddys Laboratories Inc	AUGMENTIN ES-600	amoxicillin and clavulanate potassium	43598-003	SILICON DIOXIDE
Dr Reddys Laboratories Inc	AUGMENTIN ES-600	amoxicillin and clavulanate potassium	43598-003	XANTHAN GUM
USAntibiotics LLC	AUGMENTIN ES-600	amoxicillin and clavulanate potassium	81964-003	ASPARTAME

Augmentin ES-600 Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Augmentin ES-600 is a high-strength pediatric oral suspension containing amoxicillin trihydrate equivalent to 600 mg amoxicillin and clavulanate potassium equivalent to 42.9 mg clavulanic acid per 5 mL. Its commercial value depends less on active-ingredient exclusivity than on formulation performance, palatability, reconstitution stability, dosing accuracy, supply reliability, and regulatory differentiation. The strongest opportunities are in ready-to-use pediatric antibiotics, taste-masked dry suspensions, preservative and excipient optimization, and differentiated unit-dose delivery systems.

What is Augmentin ES-600 and how is it formulated?

Augmentin ES-600 is a prescription pediatric antibacterial suspension marketed under the amoxicillin/clavulanate combination. The formulation provides a 14:1 amoxicillin-to-clavulanate ratio, a higher amoxicillin ratio than several lower-strength Augmentin suspensions. The product is intended for pediatric patients requiring high-dose amoxicillin therapy, including certain acute otitis media cases where resistant Streptococcus pneumoniae is a concern.[1]

Augmentin ES-600 active ingredients

Parameter	Product characteristic
Amoxicillin trihydrate	Equivalent to 600 mg amoxicillin per 5 mL
Clavulanate potassium	Equivalent to 42.9 mg clavulanic acid per 5 mL
Amoxicillin:clavulanate ratio	14:1
Dosage form	Powder for oral suspension
Administration	Oral
Patient segment	Primarily pediatric
Reconstituted concentration	120 mg amoxicillin and 8.58 mg clavulanate per mL
Storage after reconstitution	Refrigerated storage is required under the FDA labeling

The formulation is supplied as a dry powder and reconstituted with water before use. This approach improves chemical stability during distribution compared with shipping a fully aqueous suspension, but it transfers preparation and storage risk to the pharmacy and caregiver.

What excipients are used in Augmentin ES-600?

The FDA prescribing information identifies excipients that include aspartame, colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, sodium citrate, strawberry flavor, and xanthan gum.[1]

The principal functional roles are:

Excipient or excipient class	Likely formulation role
Xanthan gum	Suspending agent and viscosity modifier
Microcrystalline cellulose	Suspension structure and sedimentation control
Hypromellose	Viscosity enhancement and particle suspension
Colloidal silicon dioxide	Powder flow and dispersion support
Sodium citrate	Buffering and pH control
Strawberry flavor	Palatability
Aspartame	Sweetening and taste masking
Magnesium stearate	Manufacturing lubricant
Water after reconstitution	Vehicle for administration

The excipient system must balance four competing requirements: rapid redispersion, adequate viscosity, acceptable mouthfeel, and chemical stability of clavulanate. A highly viscous suspension may resist shaking and produce dose nonuniformity. A low-viscosity product may settle rapidly and deliver inconsistent doses.

What excipient strategy supports a competitive Augmentin ES-600 product?

A competitive formulation should prioritize dose uniformity and caregiver usability rather than simply matching the qualitative excipient list.

Suspension performance

Xanthan gum, microcrystalline cellulose, and hypromellose create a structured vehicle that limits sedimentation. The target is controlled flocculation or structured suspension behavior with rapid redispersion after ordinary shaking.

Critical development parameters include:

• sedimentation volume;
• redispersibility after refrigerated storage;
• viscosity across shear rates;
• particle-size distribution;
• dose uniformity throughout the bottle;
• syringe withdrawal performance;
• absence of hard caking;
• stability after repeated opening.

The product should be tested under simulated household use. Pediatric bottles may be shaken inconsistently, stored at varying refrigerator temperatures, and used over several days. A formulation that passes static laboratory testing but requires vigorous shaking has commercial risk.

Taste masking

Amoxicillin has a pronounced taste, while clavulanate can contribute bitterness and acidic or metallic notes. Aspartame and strawberry flavor are used in the reference formulation, but taste masking is a major area for differentiation.

Potential approaches include:

1. Flavor system optimization. Strawberry can be combined with masking flavors that reduce bitterness without producing an artificial aftertaste.
2. Polymer coating. Coating drug particles with a pH-sensitive or saliva-resistant polymer can reduce immediate taste perception.
3. Ion-exchange resins. Resin complexes may reduce free drug exposure in the mouth, but they require careful evaluation of release in the gastrointestinal tract.
4. Lipid or wax barriers. These may improve taste but can impair dissolution, redispersion, or manufacturing scale-up.
5. Sweetener replacement. Sucralose, acesulfame potassium, or polyol systems may offer alternatives to aspartame, subject to pediatric safety and formulation compatibility.

Taste claims require validated sensory testing. A formulation that reduces bitterness but leaves a gritty mouthfeel may perform poorly in pediatric adherence studies.

Aspartame and patient labeling

Aspartame is a source of phenylalanine. The label carries a warning for patients with phenylketonuria.[1] An aspartame-free formulation could create a modest commercial distinction, particularly in hospital formularies and pediatric practices that prefer simplified excipient labeling.

Removing aspartame is not automatically advantageous. The replacement sweetener must preserve taste, pH stability, powder flow, and suspension performance. It must also avoid excessive sweetness, laxative effects, dental-health concerns, or regulatory scrutiny associated with alternative sweeteners.

Buffer and clavulanate stability

Clavulanate is more degradation-sensitive than amoxicillin. The buffer system, water activity before reconstitution, pH after reconstitution, and storage temperature are central to shelf life.

Sodium citrate supports pH control, but changing the buffer can affect:

• clavulanate degradation;
• amoxicillin stability;
• flavor perception;
• preservative effectiveness;
• viscosity;
• dissolution;
• container compatibility.

A commercial developer should not treat buffer replacement as a simple excipient substitution. The change may require comparative stability, impurity profiling, bioequivalence support, and potentially a more extensive FDA review depending on the regulatory pathway.

What formulations are protected by Augmentin ES-600 patents?

The main commercial protection for Augmentin ES-600 historically came from the combination product, high amoxicillin-to-clavulanate ratio, dosage form, and formulation technology rather than from new chemical entity protection for either active ingredient.

Amoxicillin and clavulanate are established active ingredients. Any historical patent protection associated with Augmentin products would have been directed toward specific combinations, ratios, formulations, manufacturing processes, or methods of treatment.

What is the Orange Book status of Augmentin ES-600?

The FDA Orange Book and Drugs@FDA records are the controlling sources for listed patents, regulatory exclusivity, approved labeling, and reference-product status.[2,3] Augmentin ES-600 was approved under NDA 050755.[1,3]

For commercial planning, the product should be treated as a mature reference product rather than an actively protected innovator product with meaningful remaining core exclusivity. Generic amoxicillin/clavulanate oral suspensions and comparable high-dose products have entered the U.S. market, reducing the value of legacy formulation patents as a barrier to entry.

The relevant intellectual-property distinction is:

Protection category	Current strategic relevance
Amoxicillin composition-of-matter protection	Expired
Clavulanate composition-of-matter protection	Expired
Historic Augmentin combination patents	Generally expired or commercially weak
Product-specific formulation patents	Relevant only if unexpired and listed or enforceable
New excipient or delivery patents	Potential future differentiation
Trade secrets for flavor and process controls	Potentially useful but difficult to enforce against equivalent products

A product-specific patent search should distinguish patents covering Augmentin ES-600 itself from patents covering other Augmentin strengths or unrelated amoxicillin/clavulanate formulations. Patent families often cover multiple strengths, but claim scope may not extend to every dosage form or ratio.

When does Augmentin ES-600 lose exclusivity?

The principal exclusivity associated with Augmentin ES-600 has already elapsed. The product is in the off-patent, generic-competition phase.

FDA regulatory milestones

Milestone	Status or significance
Original Augmentin approvals	Historical approvals for amoxicillin/clavulanate products
NDA 050755	Reference NDA associated with Augmentin ES-600
Pediatric high-dose suspension	Approved for selected pediatric bacterial infections
New chemical entity exclusivity	No longer relevant
Core patent exclusivity	Historical and generally expired
Generic competition	Established for amoxicillin/clavulanate suspensions
Current commercial opportunity	Formulation, packaging, supply, and channel differentiation

The absence of meaningful core exclusivity does not eliminate commercial opportunity. It changes the investment thesis from exclusivity capture to execution, lifecycle management, and cost control.

Which companies are challenging Augmentin ES-600?

Generic manufacturers of amoxicillin/clavulanate oral suspensions are the relevant competitive group. The market includes companies that manufacture finished dosage forms and companies that supply active pharmaceutical ingredients or contract development and manufacturing services.

Competitive entry can occur through:

• ANDAs referencing the listed drug;
• authorized generic arrangements;
• private-label pediatric antibiotic products;
• hospital or group-purchasing contracts;
• regional supply agreements;
• non-U.S. products with different regulatory pathways.

A complete current list of approved ANDA holders should be taken from the FDA Orange Book and Drugs@FDA records because ownership, marketing status, and label availability can change. The strategic point is clear: a new entrant would face generic pricing pressure, not a high-value patent gate.

What Paragraph IV risks exist for Augmentin ES-600?

Paragraph IV risk is primarily historical for the mature reference product. A current ANDA applicant could challenge any remaining listed patent by asserting invalidity, unenforceability, or non-infringement. In practice, the commercial significance depends on whether an unexpired patent covers the specific 600/42.9 mg per 5 mL suspension, not merely another Augmentin strength.

A Paragraph IV strategy would require analysis of:

• patent listing accuracy;
• claim coverage of the 14:1 ratio;
• formulation claim scope;
• expiration and patent-term adjustment;
• pediatric exclusivity;
• prior litigation;
• 30-month stay eligibility;
• FDA product-specific guidance;
• tentative versus final approval status.

Because the principal active ingredients are old and generic competition exists, a late-stage Paragraph IV case would generally have lower expected value than a first generic launch involving an active composition patent.

What patent litigation affects Augmentin ES-600?

The relevant litigation history is associated with broader Augmentin and amoxicillin/clavulanate patent disputes rather than a durable, standalone patent estate for ES-600. Historic disputes involving Augmentin products addressed formulation and combination claims, including patent validity and infringement questions.

For a current entrant, litigation exposure is more likely to arise from:

• a formulation patent covering taste masking or suspension structure;
• a process patent covering dry-powder manufacture;
• a patent on a specific particle-size distribution;
• trade-secret allegations involving flavor systems;
• contract disputes with a contract manufacturer;
• trademark or trade-dress claims.

A generic manufacturer should complete a freedom-to-operate review across U.S., European, Canadian, and major emerging-market patent registers before commercial launch. U.S. freedom to operate does not establish freedom to operate in Europe, Japan, China, or Latin America.

What commercial opportunities exist for Augmentin ES-600 excipients?

Excipient suppliers

The largest opportunity is not a new active ingredient. It is a qualified excipient platform that improves manufacturing consistency or patient use.

High-value categories include:

• low-bioburden suspending polymers;
• directly compressible or free-flowing powder excipients for dry suspension manufacture;
• pediatric taste-masking systems;
• preservative-free suspension technologies;
• ready-to-use reconstitution vehicles;
• dose-uniformity enhancers;
• moisture-barrier bottle and closure systems;
• unit-dose sachets or stick packs.

A supplier that can demonstrate lower batch-to-batch viscosity variability, faster redispersion, or improved refrigerated stability may obtain value even without patent exclusivity.

Finished-dose manufacturers

A differentiated generic or branded-generic product could compete through:

Commercial position	Potential advantage
Lower-cost equivalent	Pharmacy and payer contracting
Aspartame-free product	Excipient-sensitive patients and institutions
Improved taste	Pediatric adherence
Lower viscosity	Easier oral-syringe administration
Unit-dose packaging	Emergency departments and outpatient clinics
Longer post-reconstitution stability	Reduced pharmacy waste
Ready-to-use suspension	Lower caregiver preparation burden
Dual-language packaging	International and multicultural markets
Supply assurance	Hospitals and public-health tenders

The most defensible position is a combination of measurable product performance and reliable supply. Taste alone is difficult to defend unless supported by patents, proprietary sensory data, or strong brand recognition.

How does Augmentin ES-600 compare with competing pediatric antibiotics?

Augmentin ES-600 competes with other amoxicillin/clavulanate suspensions, high-dose amoxicillin products, cephalosporin suspensions, and selected macrolides. Its principal differentiation is the high amoxicillin content relative to clavulanate, which can reduce unnecessary clavulanate exposure compared with lower-ratio products while preserving beta-lactamase inhibition.

Product characteristic	Augmentin ES-600	Lower-ratio amoxicillin/clavulanate	High-dose amoxicillin
Beta-lactamase inhibitor	Yes	Yes	No
Amoxicillin:clavulanate ratio	14:1	Often lower	Not applicable
Pediatric suspension	Yes	Yes	Yes
Diarrhea risk	Relevant	Relevant, potentially higher with more clavulanate	Generally lower from no clavulanate, but indication-dependent
Taste and adherence burden	Significant	Significant	Usually simpler
Main competitive advantage	High-dose amoxicillin with controlled clavulanate exposure	Broader legacy product range	Lower complexity and lower cost

Formulary decisions will depend on local resistance patterns, clinical guidelines, acquisition cost, tolerability, and availability.

What manufacturing and IP barriers affect new entrants?

The active ingredients are commercially available, but the finished product has technical barriers:

• clavulanate stability during powder manufacture;
• moisture control;
• uniform distribution of both actives;
• acceptable reconstitution time;
• suspension redispersibility;
• taste masking;
• microbial quality;
• bottle and closure compatibility;
• refrigerated post-reconstitution stability;
• accurate dosing with oral syringes.

Manufacturing know-how can create a practical barrier even where patent protection is weak. Critical process parameters may include blending order, lubricant addition, environmental humidity, milling conditions, powder density, and filling accuracy.

A developer should preserve process knowledge as trade secrets while seeking patents only for features that are technically distinctive and commercially important. Broad claims on conventional xanthan-gum suspensions are likely to face validity and enablement challenges.

What is the revenue exposure for Augmentin ES-600?

Public company filings generally do not isolate Augmentin ES-600 revenue from broader Augmentin or respiratory and anti-infective portfolios. Product-level revenue must therefore be estimated through prescription volume, channel data, tender awards, and market research rather than company-reported financial statements.

Revenue exposure is likely concentrated in:

• pediatric outpatient prescriptions;
• acute otitis media treatment;
• retail pharmacy;
• hospital discharge prescriptions;
• seasonal respiratory infection demand;
• government and institutional procurement.

The product is vulnerable to generic price erosion and seasonal demand variability. Its value is higher in markets where pediatric liquid antibiotics have limited competition or where supply shortages create procurement premiums.

What generic launch scenarios exist for Augmentin ES-600?

Scenario 1: Commodity generic launch

The entrant matches the reference formulation and competes on price. This has the lowest development differentiation and the highest exposure to margin compression.

Scenario 2: Taste-masked branded generic

The entrant uses a differentiated flavor and taste-masking system. Commercial success depends on clinical adherence data, pharmacy acceptance, and physician or caregiver recognition.

Scenario 3: Institution-focused product

The product is packaged for hospitals, emergency departments, and clinics. Unit-dose or ready-to-use formats can reduce dispensing errors and preparation time.

Scenario 4: Supply-reliability strategy

The manufacturer builds a dual-source active and excipient supply chain, maintains safety stock, and targets public tenders and wholesalers. This approach can outperform a lower-cost but unreliable competitor.

Scenario 5: Lifecycle extension

A new product could use an improved reconstitution vehicle, an aspartame-free system, a longer-stability formulation, or an alternative delivery device. Each change must be assessed under FDA abbreviated application or supplement requirements.

Key Takeaways

• Augmentin ES-600 contains 600 mg amoxicillin and 42.9 mg clavulanate per 5 mL in a 14:1 pediatric suspension.
• Its core active-ingredient and historic product exclusivity have expired or lost practical commercial force.
• The central technical challenge is balancing clavulanate stability, taste, viscosity, redispersibility, and dose uniformity.
• Excipients with the greatest commercial potential are suspending polymers, taste-masking systems, low-moisture powder platforms, and reconstitution technologies.
• An aspartame-free product, improved flavor, unit-dose packaging, or longer post-reconstitution stability could support a branded-generic position.
• Generic entry risk is high because the product is mature and competing amoxicillin/clavulanate suspensions are established.
• A current Orange Book and litigation review remains central to any Paragraph IV or launch decision.
• The strongest commercial thesis is formulation and supply-chain differentiation, not reliance on legacy Augmentin patent protection.

FAQs About Augmentin ES-600 Excipient and Commercial Strategy

Is Augmentin ES-600 preservative-free?

The FDA labeling identifies the inactive ingredients listed for the dry powder formulation and does not identify a conventional antimicrobial preservative as a listed excipient.[1] Microbial control depends on manufacturing quality, packaging, reconstitution practices, and storage conditions.

Can aspartame be removed from an Augmentin ES-600 generic?

Yes, a generic developer may pursue an alternative sweetener system, but the product must satisfy pharmaceutical equivalence, bioequivalence, stability, quality, and labeling requirements. The replacement must also preserve acceptable taste and suspension performance.

Is a ready-to-use Augmentin ES-600 suspension commercially attractive?

It could reduce caregiver preparation errors, but an aqueous product would face greater stability, microbial-control, shipping, and shelf-life requirements. The commercial benefit would need to offset higher manufacturing and distribution costs.

Can a new excipient create patent protection for a generic Augmentin ES-600?

A new excipient combination or use may support patent protection only if it satisfies novelty, non-obviousness, enablement, and claim-scope requirements. Conventional use of xanthan gum, hypromellose, citrate buffers, and sweeteners is unlikely to provide strong standalone protection.

Does Augmentin ES-600 have biosimilar competition?

No. Biosimilars apply to biological products. Augmentin ES-600 is a small-molecule antibacterial product, so competition proceeds through generic-drug pathways such as ANDAs rather than biosimilar applications.

References

1. U.S. Food and Drug Administration. (2024). Augmentin ES-600 prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs, NDA 050755.
4. U.S. Food and Drug Administration. (2017). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system.
5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.